Mark R. Barakat

Ophthalmology

15401 N 29th Ave
Phoenix, AZ 85053

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

HSR26-203: Financial Burden of Ocular Melanoma: A 7 Year Analysis of Trends Influencing Patient Charges and Costs to Hospitals in the Treatment of Ocular Melanoma.

HSR26-203: Financial Burden of Ocular Melanoma: A 7 Year Analysis of Trends Influencing Patient Charges and Costs to Hospitals in the Treatment of Ocular Melanoma.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 29, 2026

HSR26-199: Socioeconomic, Geographic, and Insurance-Related Disparities in Survival and Treatment Outcomes for Ocular Melanoma: A 21-Year National Inpatient Cohort Study.

HSR26-199: Socioeconomic, Geographic, and Insurance-Related Disparities in Survival and Treatment Outcomes for Ocular Melanoma: A 21-Year National Inpatient Cohort Study.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 29, 2026

Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTON.

Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTON.

Journal: Ophthalmology and therapy

Published: April 02, 2026

HSR26-199: Socioeconomic, Geographic, and Insurance-Related Disparities in Survival and Treatment Outcomes for Ocular Melanoma: A 21-Year National Inpatient Cohort Study.

HSR26-199: Socioeconomic, Geographic, and Insurance-Related Disparities in Survival and Treatment Outcomes for Ocular Melanoma: A 21-Year National Inpatient Cohort Study.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

HSR26-203: Financial Burden of Ocular Melanoma: A 7 Year Analysis of Trends Influencing Patient Charges and Costs to Hospitals in the Treatment of Ocular Melanoma.

HSR26-203: Financial Burden of Ocular Melanoma: A 7 Year Analysis of Trends Influencing Patient Charges and Costs to Hospitals in the Treatment of Ocular Melanoma.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Transforming retinal disease management through diabetes care.

Transforming retinal disease management through diabetes care.

Journal: Journal of managed care & specialty pharmacy

Published: March 28, 2025

Impact of Baseline Vision on Outcomes in Diabetic Macular Edema in VISTA/VIVID.

Impact of Baseline Vision on Outcomes in Diabetic Macular Edema in VISTA/VIVID.

Journal: Ophthalmology. Retina

Published: December 20, 2024

Human Factors Studies to Assess the Usability of the Faricimab Prefilled Syringe.

Human Factors Studies to Assess the Usability of the Faricimab Prefilled Syringe.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: October 28, 2024

Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study.

Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study.

Journal: Eye (London, England)

Published: May 22, 2024

Maculopathy after long-term use of fondaparinux, a heparin mimetic and heparanase inhibitor.

Maculopathy after long-term use of fondaparinux, a heparin mimetic and heparanase inhibitor.

Journal: American journal of ophthalmology case reports

Published: May 05, 2024

Evidence-Based Use of Bevacizumab in the Management of Neovascular Age-Related Macular Degeneration.

Evidence-Based Use of Bevacizumab in the Management of Neovascular Age-Related Macular Degeneration.

Journal: Ophthalmic surgery, lasers & imaging retina

Published: March 11, 2024

SUPRACHOROIDAL SPACE INJECTION TECHNIQUE: Expert Panel Guidance.

SUPRACHOROIDAL SPACE INJECTION TECHNIQUE: Expert Panel Guidance.

Journal: Retina (Philadelphia, Pa.)

Published: March 07, 2024

Showing 1-12 of 28

Last Updated: 09/26/2026